MWVC
AERI

Morgens Waterfall Vintiadis & Co’s Aerie Pharmaceuticals AERI Stock Holding History

Morgens Waterfall Vintiadis & Co’s Portfolio AERI Stock Details AERI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-80,000
Closed -$1.28M – 39
2021
Q2 		$1.28M Hold
80,000
– – 0.65% 30
2021
Q1 		$1.43M Hold
80,000
– – 0.79% 31
2020
Q4 		$1.08M Buy
+80,000
New +$967K 0.58% 29

Other funds holding AERI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return

Morgens Waterfall Vintiadis & Co's AERI Position: Q3 2021 in Review

Morgens Waterfall Vintiadis & Co sold out of Aerie Pharmaceuticals (AERI) in Q3 2021, closing a stake of 80,000 shares — an estimated $1.28M sold.

Morgens Waterfall Vintiadis & Co first reported a position in AERI in Q4 2020 and held it in 3 quarters. The position peaked at $1.43M in Q1 2021. 137 funds tracked by Wall St. Rank hold AERI as of Q3 2021.

  • Morgens Waterfall Vintiadis & Co reported no remaining Aerie Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Morgens Waterfall Vintiadis & Co sold 80,000 Aerie Pharmaceuticals shares in Q3 2021, an estimated $1.28M.
  • Morgens Waterfall Vintiadis & Co first reported a position in Aerie Pharmaceuticals in Q4 2020 and held it in 3 quarters.
  • Morgens Waterfall Vintiadis & Co's Aerie Pharmaceuticals position peaked at $1.43M in Q1 2021.
  • 137 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q3 2021.

Based on Morgens Waterfall Vintiadis & Co's 13F filing for Q3 2021, filed 15 Nov 2021.